Association of homocysteine with hippocampal volume independent of cerebral amyloid and vascular burden

Neurobiology of Aging

Volumn 35, Issue 7, 2014, Pages 1519-1525

  Choe, Young Min ^a   Sohn, Bo Kyung ^b   Choi, Hyo Jung ^a   Byun, Min Soo ^a   Seo, Eun Hyun ^a   Han, Ji Young ^a   Kim, Yu Kyeong ^b   Yoon, Eun Jin ^b   Lee, Jong Min ^c   Park, Jinsick ^c   Woo, Jong Inn ^a   Lee, Dong Young ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Alzheimer's disease; Amyloid; Hippocampus; Homocysteine; Mild cognitive impairment; PIB; Vascular burden

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGE; AGED; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; APOE 4 GENE; ARTICLE; BODY MASS; BRAIN SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLIC ACID BLOOD LEVEL; GENDER; GENOTYPE; GRAY MATTER; HIPPOCAMPUS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; VITAMIN BLOOD LEVEL; WHITE MATTER;

ALZHEIMER'S DISEASE; AMYLOID; HIPPOCAMPUS; HOMOCYSTEINE; MILD COGNITIVE IMPAIRMENT; PIB; VASCULAR BURDEN;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; COGNITION DISORDERS; FEMALE; HIPPOCAMPUS; HOMOCYSTEINE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; RISK FACTORS;

EID: 84903372232     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.01.013     Document Type: Article

References (46)

1. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. Aquantitative assessment of plasma homocysteine as a risk factor for vascular-disease-probable benefits of increasing folic-acid intakes. JAMA 1995, 274:1049-1057.
2. Choo I.H., Lee D.Y., Kim J.W., Seo E.H., Lee D.S., Kim Y.K., Kim S.G., Park S.Y., Woo J.I., Yoon E.J. Relationship of amyloid-beta burden with age-at-onset in Alzheimer disease. Am. J. Geriatr. Psychiatry 2011, 19:627-634. 10.1097/JGP.0b013e318202bf3a.
3. Choo I.H., Lee D.Y., Oh J.S., Lee J.S., Lee D.S., Song I.C., Youn J.C., Kim S.G., Kim K.W., Jhoo J.H., Woo J.I. Posterior cingulate cortex atrophy and regional cingulum disruption in mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2010, 31:772-779. 10.1016/j.neurobiolaging.2008.06.015.
4. Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., Ueland P.M. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 1998, 55:1449-1455.
5. Collins D.L., Neelin P., Peters T.M., Evans A.C. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J.Comput. Assist. Tomography 1994, 18:192-205.
6. DeCarli C., Mungas D., Harvey D., Reed B., Weiner M., Chui H., Jagust W. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2004, 63:220-227.
7. den Heijer T., Vermeer S.E., Clarke R., Oudkerk M., Koudstaal P.J., Hofman A., Breteler M.M. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 2003, 126(Pt 1):170-175.
8. Fazekas F., Chawluk J.B., Alavi A., Hurtig H.I., Zimmerman R.A. Mr signal abnormalities at 1.5-T in Alzheimer's dementia and normal aging. Am. J. Neuroradiol. 1987, 8:421-426.
9. Feng L., Isaac V., Sim S., Ng T.P., Krishnan K.R.R., Chee M.W.L. Associations between elevated homocysteine, cognitive impairment, and reduced white matter volume in healthy old adults. Am. J. Geriatr. Psychiatry 2013, 21:164-172. 10.1016/j.jagp.2012.10.017.
10. Fotuhi M., Do D., Jack C. Modifiable factors that alter the size of the hippocampus with ageing. Nat. Rev. Neurol. 2012, 8:189-202. 10.1038/nrneurol.2012.27.
11. Gemmell E., Bosomworth H., Allan L., Hall R., Khundakar A., Oakley A.E., Deramecourt V., Polvikoski T.M., O'Brien J.T., Kalaria R.N. Hippocampal neuronal atrophy and cognitive function in delayed poststroke and aging-related dementias. Stroke 2012, 43:808-814. 10.1161/Strokeaha.111.636498.
12. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
13. Ho P.I., Collins S.C., Dhitavat S., Ortiz D., Ashline D., Rogers E., Shea T.B. Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J.Neurochem. 2001, 78:249-253.
14. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128. 10.1016/S1474-4422(09)70299-6.
15. Jiang J., Sachdev P., Lipnicki D.M., Zhang H., Liu T., Zhu W., Suo C., Zhuang L., Crawford J., Reppermund S., Trollor J., Brodaty H., Wen W. Alongitudinal study of brain atrophy over two years in community-dwelling older individuals. NeuroImage 2013, 10.1016/j.neuroimage.2013.08.022.
16. Kim K.W., Jhoo J.H., Lee K.U., Lee D.Y., Lee J.H., Youn J.Y., Lee B.J., Han S.H., Woo J.I. Association between apolipoprotein E polymorphism and Alzheimer's disease in Koreans. Neurosci. Lett. 1999, 277:145-148. 10.1016/S0304-3940(99)00867-8.
17. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 2004, 55:306-319. 10.1002/ana.20009.
18. Kruman I.I., Culmsee C., Chan S.L., Kruman Y., Guo Z., Penix L., Mattson M.P. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J.Neurosci. 2000, 20:6920-6926.
19. Lee D.Y., Lee K.U., Lee J.H., Kim K.W., Jhoo J.H., Kim S.Y., Yoon J.C., Woo S.I., Ha J., Woo J.I. Anormative study of the CERAD neuropsychological assessment battery in the Korean elderly. J.Int. Neuropsychol. Soc. 2004, 10:72-81. 10.1017/S1355617704101094.
20. Lee J.H., Lee K.U., Lee D.Y., Kim K.W., Jhoo J.H., Kim J.H., Lee K.H., Kim S.Y., Han S.H., Woo J.I. Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries. J.Gerontol. B Psychol. Sci. Soc. Sci. 2002, 57:P47-P53.
21. Lipton S.A., Kim W.K., Choi Y.B., Kumar S., D'Emilia D.M., Rayudu P.V., Arnelle D.R., Stamler J.S. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U.S.A 1997, 94:5923-5928.
22. Lopresti B.J., Klunk W.E., Mathis C.A., Hoge J.A., Ziolko S.K., Lu X., Meltzer C.C., Schimmel K., Tsopelas N.D., DeKosky S.T., Price J.C. Simplified quantification of Pittsburgh compound-B amyloid imaging PET studies: a comparative analysis. J.Nucl. Med. 2005, 46:1959-1972.
23. McCaddon A., Regland B., Hudson P., Davies G. Functional vitamin B(12) deficiency and Alzheimer disease. Neurology 2002, 58:1395-1399.
24. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
25. Nurk E., Refsum H., Tell G.S., Engedal K., Vollset S.E., Ueland P.M., Nygaard H.A., Smith A.D. Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine Study. Ann. Neurol. 2005, 58:847-857. 10.1002/ana.20645.
26. Perna A.F., Ingrosso D., De Santo N.G. Homocysteine and oxidative stress. Amino acids 2003, 25:409-417. 10.1007/s00726-003-0026-8.
27. Perry I.J., Refsum H., Morris R.W., Ebrahim S.B., Ueland P.M., Shaper A.G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995, 346:1395-1398.
28. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J.Intern. Med. 2004, 256:183-194. 10.1111/j.1365-2796.2004.01388.x.
29. Prins N.D., Den Heijer T., Hofman A., Koudstaal P.J., Jolles J., Clarke R., Breteler M.M. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology 2002, 59:1375-1380.
30. Ravaglia G., Forti P., Maioli F., Martelli M., Servadei L., Brunetti N., Porcellini E., Licastro F. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am. J. Clin. Nutr. 2005, 82:636-643.
31. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., Caselli R.J. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 2009, 106:6820-6825. 10.1073/pnas.0900345106.
32. Sachdev P.S. Homocysteine and brain atrophy. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2005, 29:1152-1161. 10.1016/j.pnpbp.2005.06.026.
33. Sachdev P.S., Valenzuela M., Wang X.L., Looi J.C., Brodaty H. Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 2002, 58:1539-1541.
34. Selhub J., Jacques P.F., Bostom A.G., Dagostino R.B., Wilson P.W.F., Belanger A.J., Oleary D.H., Wolf P.A., Schaefer E.J., Rosenberg I.H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. New Engl. J. Med. 1995, 332:286-291.
35. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New Engl. J. Med. 2002, 346:476-483. 10.1056/NEJMoa011613.
36. Seshadri S., Wolf P.A., Beiser A.S., Selhub J., Au R., Jacques P.F., Yoshita M., Rosenberg I.H., D'Agostino R.B., DeCarli C. Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch. Neurol. 2008, 65:642-649. 10.1001/archneur.65.5.642.
37. Sled J.G., Zijdenbos A.P., Evans A.C. Anonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 1998, 17:87-97. 10.1109/42.668698.
38. Smith A.D., Smith S.M., de Jager C.A., Whitbread P., Johnston C., Agacinski G., Oulhaj A., Bradley K.M., Jacoby R., Refsum H. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PloS One 2010, 5:e12244. 10.1371/journal.pone.0012244.
39. Smith S.M. Fast robust automated brain extraction. Hum. Brain Mapp. 2002, 17:143-155. 10.1002/hbm.10062.
40. Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ullmann D., Tishler P.V., Hennekens C.H. Aprospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268:877-881.
41. Swan G.E., DeCarli C., Miller B.L., Reed T., Wolf P.A., Carmelli D. Biobehavioral characteristics of nondemented older adults with subclinical brain atrophy. Neurology 2000, 54:2108-2114.
42. Tangney C.C., Aggarwal N.T., Li H., Wilson R.S., Decarli C., Evans D.A., Morris M.C. Vitamin B12, cognition, and brain MRI measures: a cross-sectional examination. Neurology 2011, 77:1276-1282. 10.1212/WNL.0b013e3182315a33.
43. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 2002, 15:273-289. 10.1006/nimg.2001.0978.
44. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., Ames D., Rowe C.C., Masters C.L., Australian Imaging Biomarkers, Lifestyle Research Group Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367. 10.1016/S1474-4422(13)70044-9.
45. Williams J.H., Pereira E.A., Budge M.M., Bradley K.M. Minimal hippocampal width relates to plasma homocysteine in community-dwelling older people. Age and ageing 2002, 31:440-444.
46. Zijdenbos A., Evans A., Riahi F., Sled J., Chui J., Kollokian V. Automatic quantification of multiple sclerosis lesion volume using stereotaxic space. Lect. Notes Comput. Sc. 1996, 1131:439-448.